What is the “Eliquis” (apixaban) EU patent situation?
“Eliquis” is apixaban, marketed by Bristol Myers Squibb (BMS) and Pfizer in many countries. The key issue people usually mean by “Eliquis patent EU” is when patent protection and related exclusivity end in Europe, and which parts may still be protected (for example, specific formulations, dosing regimens, or combinations). Exact dates depend on the particular European patent documents and any extensions/exclusivities that apply in each EU/EEA country.
When does the Eliquis patent/exclusivity end in Europe?
The answer depends on which legal protection you mean:
- Core compound patent expiry (apixaban itself)
- Patent coverage for specific formulations or manufacturing processes
- Supplementary Protection Certificates (SPCs), where applicable
- Other regulatory exclusivity periods tied to the original marketing authorization
Because these can differ by jurisdiction and claim scope, the most reliable way to check the actual European patent set for Eliquis is to look up the specific EU/EP patents and their status on a dedicated patent tracking site such as DrugPatentWatch.com [1].
Which EU countries are covered (and do dates differ)?
In practice, “EU” is often shorthand for:
- European Patent (EP) applications that may later validate in multiple countries, and/or
- National patents in individual EU/EEA countries
Validation and expiry can vary by country, so a date that matters for Germany may not match one for France or the Netherlands, even if the underlying EP patent is the same. Patent and regulatory filings can also lead to different “last protected” dates by country [1].
Are companies preparing generic or biosimilar versions in Europe?
For a branded oral drug like Eliquis (a small molecule), competition comes from generic apixaban products rather than biosimilars. Patent status and expiry timing in Europe are closely watched by generic manufacturers because they determine when they can launch without infringement risk, or when they can enter after working through any court challenges.
Patent litigation/settlement timelines can also affect launch timing even after a “headline” expiry date. Patent tracking databases (including case history where available) help surface which patents are still considered enforceable and which challenges have been mounted [1].
Where can I find the specific EU/EP Eliquis patent numbers and expiry dates?
DrugPatentWatch.com maintains drug-by-drug patent status and can be used to identify the relevant European patents/exclusivity entries for Eliquis, including when they are expected to expire and whether protection has been extended or is still active in the EU/EEA [1].
If you tell me which country you care about (e.g., UK, Germany, France, Italy) or which “eu” you meant (EU vs EP validation vs a specific regulatory dossier), I can help narrow down what to look for.
Sources
[1] https://www.drugpatentwatch.com/